Clinical data and state rules are separate facts. Both are shown; neither is a decision.
Repeated dosing inhibited CYP2D6, CYP2C9 and CYP3A4 in healthy volunteers. Lowers glucose; meta-analyses found no significant increase in hypoglycemia, though additive effects with diabetes drugs are expected. Relevance of these CYP effects to psilocin clearance is uncertain.
No provision names this medication or its class.
Colorado · checked 2026-09-30No provision names this medication or its class.
Oregon · checked 2026-09-30New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.
New Mexico · checked 2026-09-30No condition named in state rules is linked to this medication.